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Abstract 
One of the most promising classes of iron chelators are α-N-heterocyclic thiosemicarbazones with 
Triapine as the most prominent representative. In several clinical trials Triapine showed 
anticancer activity against hematological diseases, however, studies on solid tumors failed due to 
widely unknown reasons. Some years ago, it was recognized that “terminal dimethylation” of 
thiosemicarbazones can lead to a more than 100-fold increased activity, probably due to 
interactions with cellular copper depots. To better understand the structural requirements for the 
switch to nanomolar cytotoxicity, we systematically synthesized all eight possible N-methylated 
derivatives of Triapine and investigated their potential against Triapine-sensitive as well as -
resistant cell lines. While only the “completely” methylated compound exerted nanomolar 
activity, the data revealed that all compounds with at least one N-dimethylation were not affected 
by acquired Triapine resistance. In addition, these compounds were highly synergistic with 
copper treatment accompanied by induction of ROS and massive necrotic cell death.  
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Introduction 
Due to the limited success of chemotherapeutic agents in the treatment of advanced cancer, novel 
anticancer drugs with different mechanisms of action need to be developed. One possibility is to 
target the deregulated iron metabolism of rapidly dividing cancer cells1, 2. Therefore, several iron 
chelators have been developed. The first candidate with potential anticancer activity was 
desferrioxamine (DFO)2, which entered clinical trials in the 1980s and showed remarkable results 
in leukemia3 as well as neuroblastoma patients4. Nevertheless, subsequent studies demonstrated 
failure of DFO as a potent anticancer agent5, 6 which was at least in part connected with the very 
short half-life time and low membrane permeability of this compound7. Consequently, numerous 
other iron chelating drugs have been developed to overcome these limitations2, 8. One very 
promising class of iron chelators are α-N-heterocyclic thiosemicarbazones which harbor a N,N,S 
tridentate motif able to strongly coordinate to transition metal ions9, 10. The most prominent and 
best characterized member is 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, also known 
as 3-AP or Triapine7. Triapine is a highly efficient inhibitor of ribonucleotide reductase11 (via 
destruction of the iron-dependent tyrosyl radical12), a crucial enzyme for the synthesis of dNTPs. 
In addition, also other thiosemicarbazones like di-2-pyridylketone 4,4-dimethyl-3-
thiosemicarbazone (Dp44mt) and di-2-pyridylketone-4-cyclohexyl-4-methyl-3-
thiosemicarbazone (DpC) are currently intensively investigated as drug candidates13. With regard 
to the clinical situation, Triapine showed promising anticancer activity in several clinical phase I 
and II trials on patients with hematological diseases14, 15, while studies on solid tumors failed so 
far16-18. The reason for this lack of efficiency against solid tumors is currently not fully 
understood, but one hypothesis is rapid development of resistance. Therefore, our group has 
recently generated a Triapine-resistant colon carcinoma cell line to investigate the mechanisms 
underlying acquired Triapine resistance in solid cancer cells. Interestingly, very rapid up-
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regulation of well-known multi-drug resistance mechanisms, such as ABCB1 (P-glycoprotein) 
and protein kinase C, were found, although Triapine is only a weak substrate for ATP-binding 
cassette transporters19. 
In order to improve thiosemicarbazone-based therapy, in the last years multiple novel derivatives 
have been developed resulting in the discovery of several compounds with a distinctly increased 
cytotoxicity. One of these compounds was the α-pyridyl thiosemicarbazone Dp44mT which 
exhibited a more than 100-fold higher cytotoxicity than Triapine20-22. This strongly increased 
activity was also shared by some other α-N-heterocyclic thiosemicarbazones published by our 
group and seems to be associated with the so-called “terminal dimethylation” (lack of hydrogen 
atoms at the terminal nitrogen atom)23, 24. Interestingly, at least in case of Dp44mT, the improved 
anticancer activity was so far explained by interaction with cellular copper ions, which results in 
oxidative stress and apoptosis induction25-27. In order to fill the knowledge gap regarding the 
anticancer mechanisms of Triapine and the terminally dimethylated nanomolar cytotoxic 
derivatives, in this work, systematically all possible N-methylated derivatives of Triapine 
(Scheme 1) were synthesized and their physico-chemical as well as anticancer properties were 
analyzed. In particular, we focused on the detailed structure-activity relationship, mode of action 
studies and the impact of acquired Triapine resistance on the activity of the novel derivatives.  
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Scheme 1: Library of the investigated compounds. Reaction conditions: (i) (Boc)2O, sodium 
bis(trimethylsilyl)amide; (ii) NaH, MeI; (iii) n-BuLi, DMF; (iv) respective thiosemicarbazide.  
 
Results  
Synthesis and characterization. The novel monomethylated 3-aminopyridine derivatives were 
synthesized by treatment of Boc-protected 3-amino-2-bromopyridine with methyl iodide in the 
presence of NaH. For dimethylation 3-amino-2-bromopyridine was directly treated with excess 
methyl iodide/NaH. Subsequently, in both cases, the bromo species were converted to the 
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respective aldehydes using n-buthyllithium (n-BuLi) and dimethylformamide (DMF), which were 
finally reacted with the respective thiosemicarbazides (Scheme 1). For the monomethylated 3-
aminopyridine derivatives, in the last step, conc. HCl was added for deprotection resulting in 
formation of the HCl salts (Scheme 1).  
The 1H-NMR spectra of the H2NNR2 series in dimethylsulfoxide (DMSO)-d6 showed only one 
isomeric form with the N-NH signal around 11.1–11.4 ppm. This indicates the presence of the so-
called E-isomer of 2-formylpyridine thiosemicarbazones28. Also the HCl-salts of the MeHNNR2 
series resonated in this region (11.8–12.2). In contrast, for all three Me2NNR2 derivatives two 
sets of signals could be observed in DMSO-d6: the E-isomer again in the region 11.1–11.6 ppm 
and a second N-NH signal between 13.9–15.2 ppm attributed to the Z-isomer. This strong low 
field shift can be explained by the involvement of the N-NH moiety in an intramolecular 
hydrogen bond. This bond also strongly influences the shift of the HC=N proton (E-isomer: ~8.5, 
Z-isomer: ~7.5) and the corresponding carbon C=N signal (E-isomer: ~142 ppm, Z-isomer: ~132 
ppm). Noteworthy, in case of Me2NNH2 and Me2NNHMe, the unpurified spectra showed both 
isomers, whereas after chromatographic purification only the pure E-isomer was present. In 
contrast, for Me2NNMe2 both isomers were observed in the NMR spectrum after column 
chromatography. 
X-ray quality crystals of Me2NNH2 were obtained from a water solution stored at 4°C. Results of 
X-ray diffraction analysis are shown in Figure 1A, together with selected bond lengths and 
angles. Me2NNH2 crystallized in the monoclinic space group P21/c and adopts the Z-isomeric 
form, with a hydrogen bond between N1 and N4, in contrast to Triapine with E-configuration23.  
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Figure 1: A) X-ray crystal structure of Me2NNH2. The thermal ellipsoids are drawn at 50% 
probability levels. Selected bond lengths (Å) and angles (deg): C6N3 1.2957(15), N3N4 
1.3649(14), N4C7 1.3526(15), C7S1 1.6850(12), C7N5 1.3272(16) Å; Θ(N2C4C5C6) –
5.88(17), Θ(C5C6N3N4) –0.84(18), Θ(N3N4C7S1) 177.52(8)°. B) 3D fluorescence spectrum of 
MeHNNH2 in 1% DMSO/PBS (10 µM) at pH 7.4. 
Due to the intrinsic fluorescence properties of Triapine, 29 the series of new derivatives was also 
investigated by fluorescence spectroscopy (conditions: 10 µM in 1% DMSO/phosphate buffered 
saline (PBS), pH 7.4). Maximum of the excitation wavelength, emission wavelength and intensity 
of emitted fluorescence light are listed in Table 1 and a 3D fluorescence plot of MeHNNH2 is 
shown in Figure 1B. Concerning the fluorescence intensity, no general trends could be observed, 
only the Me2NNR2 series showed distinctly lower intensity compared to the other derivatives. 
The maxima of the excitation wavelengths correlate as expected with the highest bands at the 
highest max in the UV/vis spectra. Noteworthy, the excitation maximum increases from the 
H2NNR2 series at ~370 nm to the MeHNNR2 derivatives at ~400 nm. However, unexpectedly it 
strongly decreases to ~350 nm in the three Me2NNR2 compounds.  
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Table 1: Fluorescence data of Triapine and its derivatives  
Compounda Excitation 
maximum 
/nm 
Emission 
maximum 
/nm 
Counts per 
secondb 
Triapine 368 454 1,360,000 
H2NNHMe 364 448 1,109,300 
H2NNMe2 368 422 1,530,600 
MeHNNH2 396 482 2,360,200 
MeHNNHMe 392 482 1,524,900 
MeHNNMe2 396 492 378,600 
Me2NNH2 352 506 409,200 
Me2NNHMe 352 500 731,300 
Me2NNMe2 352 482 670,700 
aDMSO stock solutions of all compounds were diluted with PBS (pH 7.4) to a final concentration 
of 10 µM (1% DMSO); b Measured at the maxima of the excitation and emission wavelengths. 
The lipo-hydrophilic character of the compounds was studied at pH 7.4 via partitioning between 
n-octanol and water (Table 2). According to the pKa values of Triapine and H2NNMe2, both are 
neutral (100% HL) at pH 7.430, which can also be expected for the other derivatives. Thus, the 
logD7.4 values are considered to be equal to the logP values of the compounds.  
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Table 2: Log D7.4 values (n-octanol/water) for the Triapine derivatives [25 °C, pH = 7.40, 10 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and I = 0.10 M (KCl)]. 
 
λmax / nm 
(water) 
λmax / nm 
(n-octanol) 
logD7.4 SD 
logP predicted with 
Chemdraw 
Triapine 360 376    0.85 a - –0.02 
H2NNHMe 360 372 1.20 0.03 0.50 
H2NNMe2 362 374    1.30 
b - 0.88 
  
MeHNNH2 386 396 1.40 0.10 0.28 
MeHNNHMe 384 392 2.03 0.10 0.80 
MeHNNMe2 386 394 2.10 0.01 1.18 
  
Me2NNH2 348 364 1.21 0.02 1.07 
Me2NNHMe 350 364 1.86 0.01 1.59 
Me2NNMe2 352 372 1.52 0.03 1.97 
a Value is taken from Ref [30]; b Value is taken from Ref [31] 
 
Stepwise methylation of Triapine up to MeHNNMe2 as expected increased the lipophilicity. 
Noteworthy, the methylation of NH2 → NHMe had a much stronger influence on the lipophilicity 
compared to the NHMe → NMe2 step. However, again trends of the Me2NNR2 derivatives did 
not correlate with all other compounds. Unexpectedly, the logD7.4 values were below that of the 
MeHNNR2 series and, in addition, there was no stepwise increase from terminal NH2 to NMe2. In 
general, the obtained logD7.4/P values were much higher than the values predicted with 
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ChemDraw software. This once again confirms that the calculation of logP values is often 
afflicted with errors (especially when isomerization or intermolecular bonding is non-
considered). 
Synthesis and investigation of isomers. The fact that the physico-chemical parameters (UV/vis 
and fluorescence maxima, lipophilicity) of the three derivatives of the Me2NNR2 series did not fit 
into the expected range, prompted us to further investigate this set of compounds. As the NMR 
spectra of the Me2NNH2 series already indicated the presence of two isomers (in contrast to the 
other six compounds), we aimed to isolate both isomers as pure compounds. In case of Me2NNH2 
and Me2NNHMe, the standard synthesis with chromatographic purification already yielded the 
pure E isomers. To obtain the respective Z isomers, the E isomers were stirred in acetonitrile for 
24 h at 37°C. This was necessary because solvents with a low donor number32 were previously 
reported to stabilize the Z isomer28, 33. Indeed, this approach resulted in partial conversion of the 
two compounds and allowed isolation of the pure Z isomers of Me2NNH2 and Me2NNHMe after 
chromatographic separation. For Me2NNHMe2, the isomers could not be separated due to a very 
fast interconversion.  
As next step, the isomerization process of all nine compounds including the purified E and Z 
isomers of Me2NNH2 and Me2NNHMe were studied in PBS at pH 7.4 via high-performance 
liquid chromatography (HPLC) coupled to a mass spectrometry (MS) detector (Table 3).  
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Table 3: Isomerization study in PBS at pH 7.4 via HPLC-MS.a 
Compound 0 h 24 h 
  % Isomer 1 % Isomer 2 % Isomer 1 % Isomer 2 
Triapine 100 (7.7)b - 100 - 
H2NNHMe 100 (10.0) - 100 - 
H2NNMe2 100 (10.2) - 100 - 
MeHNNH2 100 (10.5) - 100 - 
MeHNNHMe 99 (11.3) 1 (9.8)b 99 1 
MeHNNMe2 98 (11.3) 2 (10.3) 98 2 
(E)-Me2NNH2 -  100 (10.3) 8 92 
(Z)-Me2NNH2 94 (13.9) 6 (10.3)  6 94 
(E)-Me2NNHMe 4 (16.3) 96 (11.1) 15 85 
(Z)-Me2NNHMe 93 (16.3) 7 (11.1) 13 87 
Me2NNMe2 
c c c c 
a DMSO stock solutions of all compounds were diluted with PBS (pH 7.4) to a final concentration 
of 50 µM (1% DMSO) and immediately measured by HPLC-MS. All measured values are ±2%. b 
The numbers in brackets correspond to the HPLC-MS retention time (min) of the compounds. c In 
case of Me2NNMe2, only one very broad peak was obtained, which was not possible to be 
separated into the two isomers, presumably due to the fast interconversion on the column. 
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In aqueous solution, the N-NH protons, which are usually used for the assignment of E and Z 
isomer in organic solvents via NMR spectroscopy, are not detectable anymore. Thus, for the 
HPLC measurements, the respective retention times were used as assignment parameters (the 
different isomers were termed isomer 1 and 2). The measurements performed directly after 
dissolution in PBS showed a clear increase of the retention times with increasing number of 
methyl groups. Consequently, Triapine was found at 7.7 min, followed by MeHNNMe2 at 11.3 
min, (Z)-Me2NNH2 at 13.9 min and finally (Z)-Me2NNHMe at 16.3 min. For Me2NNMe2 only a 
very broad peak was observed, presumably due to fast interconversion of the isomers on the 
column. In contrast, the synthesized E-isomers are not in line with this trend, with (E)-Me2NNH2 
at 10.3 min and (E)-Me2NNHMe at 11.1 min. After 24 h the isomeric pattern was identical for 
all derivatives, except for the purified E and Z isomers of Me2NNH2 and Me2NNHMe, which 
interconverted and reached an equilibrium with ~90% isomer 2 and 10% isomer 1 (Figure 2). In 
contrast to all other derivatives, in case of Me2NNH2 and Me2NNHMe, the isomer 2 was 
stabilized in PBS solution. This could explain why the measured UV/vis and fluorescence 
maxima as well as lipophilicity do not follow a clear trend within all nine compounds.  
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Figure 2: Interconversion of isomer 1 (black) and isomer 2 (red) of Me2NNH2 in PBS at pH 7.4. 
 
Cytotoxicity. To assess the impact of the structural modifications in the Triapine backbone on 
the antitumor activity, Triapine and its eight derivatives were tested against the colon 
adenocarcinoma SW480, the ovarian carcinoma A2780, selected Triapine-resistant SW480/Tria 
cells19, the cervix carcinoma KB-3-1 together with its ABCB1-overexpresing subline KBC-1, and 
finally the lung fibroblast line Wi38. To this end, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays were performed after 72 h of drug incubation. 
In the cancer cell model, all compounds revealed IC50 values in the low µM range with rather 
minor differences (Table 4). The only remarkable exception was Me2NNMe2, exerting extremely 
increased activity with IC50 values in the low nM range. With regard to the structural differences, 
in the chemosensitive A2780 and SW480, terminal monomethylation in case of H2NNHMe and 
0 h
1 h
24 h
3 h
Retention Time [min] 
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MeHNNHMe resulted in decreased activity (e.g. in SW480 cells by 2.9- and 2.3-fold, 
respectively) compared to the terminal NH2 derivatives. In contrast, terminal dimethylation 
showed a tendency to increase the cytotoxicity in case of H2NNMe2 and MeHNNMe2. Also 
monomethylation of the pyridine NH2 slightly decreased the anticancer activity in both cells lines 
compared to the non-methylated derivatives. Notably, dimethylation of the pyridine NH2 resulted 
in strong variances between the individual experiments, indicated by the rather high standard 
deviations of the respective IC50 values. Interestingly, these are exactly the derivatives where the 
presence of different isomers was observed (in case of Me2NNH2 and Me2NNMeH, both the 
isomeric mixture and the pure E and Z isomers were tested, however, without significant 
differences). Furthermore, clearly diminished activity of Me2NNH2 compared to Triapine as well 
as a dramatic increase from H2NNMe2 to Me2NNMe2 (43-fold in A2780 cells) was found, 
resulting in nanomolar activity for Me2NNMe2. 
Interestingly, Triapine-resistant SW480/Tria cells responded differently as compared to the 
parental SW480 cells. In general, with increasing number of methylation sites also the 
cytotoxicity increased regardless whether methylation was at the pyridine NH2 or at the terminal 
NH2 position. Hence, the observed order of activity was Triapine < H2NNHMe < H2NNMe2 and 
Triapine < MeHNNH2 < Me2NNH2. Me2NNMe2 again was the most active thiosemicarbazone, 
with IC50 values in the nM range. Also the degree of resistance (resistance factor is shown in 
Table 4) markedly decreased with increased methylation of the pyridine NH2 and terminal NH2 
groups. Thus, SW480/Tria cells were highly cross-resistant against Triapine derivatives with one 
methyl group (H2NNHMe and MeHNNH2). For MeHNNHMe, the activity was not diminished 
in the Triapine-resistant cell model. In contrast, for all thiosemicarbazones, with at least one 
NMe2 moiety, the activity was even higher in the Triapine-resistant cell line compared to the 
parental SW480 cells (in most cases the IC50 levels were about ~0.5-fold compared to the 
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parental cells). However, due to the high standard deviation of the derivatives with dimethylation 
of the pyridine NH2, only MeHNNMe2 reached statistical significance). This clearly indicates 
that dimethylation of one of the two amino groups is able to efficiently overcome acquired 
Triapine resistance or even induce a tendency towards collateral sensitivity. To investigate also 
the contribution of ABCB1 expression on the activity, our test panel was additionally tested on  
KB-3-1 cells in comparison to its highly ABCB1-overexpressing subline KBC-1. In agreement to 
our previous publication19, KBC-1 displayed a weak (2.9-fold) resistance to Triapine and closely 
related derivatives like H2NNHMe, MeHNNH2, MeHNNHMe, whereas drug resistance was 
reduced (not significant) by terminal dimethylation. However, dimethylation at the pyridine NH2 
in case of Me2NNH2 and Me2NNHMe induced significant collateral sensitivity of KBC-1 cells.  
Finally, the impact of our test panel on non-malignant lung fibroblasts (WI38) was investigated. 
Overall, this cell line was in general less sensitive towards our compound panel than the cancer 
cell lines, especially A2780. However, it might be worth noting that the structure-activity 
relationship of WI-38 differed to some extent from the cancer cell models. Such, it displayed the 
highest sensitivity towards all compounds harboring a terminal dimethylation (H2NNMe2, 
MeHNNMe2, Me2HNNMe2), with IC50 values ~1 µM. This also implies that Me2NNMe2 
showed no nanomolar activity in this cell model. Overall, these data indicate a cancer cell-
specific activity window for several compounds of our panel including Me2HNNMe2. This is 
also supported by preliminary toxicity tests of Me2NNMe2 in mice revealing no differences in the 
tolerability compared to e.g. Triapine. 
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Table 4: IC50 values (µM) of Triapine and its derivatives in different cancer cell lines after 72 h 
drug treatment. 
Compound A2780 SW480 SW480/Tria  
(resistance 
factor) 
KB-3-1 KBC-1 
(resistance 
factor) 
WI-38 
Triapine 
0.7 ± 0.3 0.84 ± 0.25 
> 50  
(>60)*** 
3.1 ± 1.2 
8.9 ± 0.4 
(2.9)*** 
> 25 
H2NNHMe 
0.9 ± 0.1 2.51 ± 0.58 
9.5 ± 0.7 
(3.8)*** 
4.7 ± 1.2 
20.9 ± 1.3 
(4.4)*** 
> 25 
H2NNMe2 
0.30 ± 0.03 0.52 ± 0.25 
0.3 ± 0.1 
(0.6)n.s. 
0.79 ± 0.08 
1.4 ± 0.8 
(1.8)n.s. 
1.1 ± 0.8 
MeHNNH2 
0.6 ± 0.2 1.37 ± 0.54 
10.0 ± 0.04 
(7.3)*** 
2.3 ± 0.6 
10.3 ± 2.2 
(4.5)** 
11.3 ± 
1.9 
MeHNNHMe 
1.1 ± 0.3 3.16 ± 0.80 
4.6 ± 0.6 
(1.5)* 
4.4 ± 0.3 
9.5 ± 2.7 
(2.2)* 
9.2 ± 0.4 
MeHNNMe2 
0.40 ± 0.03 1.36 ± 0.98 
0.30 ± 0.06 
(0.2)* 
4.2 ± 0.3 
3.1 ± 0.8 
(0.7)n.s. 
1.7 ± 0.7 
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Me2NNH2 
6.4 ± 1.1 5.97 ± 3.02 
4.8 ± 3.6 
(0.8)n.s. 
>50 
14.6 ± 6.2 
(<0.3)*** 
11.2 ± 
4.2 
Me2NNHMe 
0.9  ± 0.2 5.98 ± 3.06 
2.9 ± 0.7 
(0.5)n.s. 
>50 
7.2 ± 4.2 
(<0.2)*** 
5.2 ± 1.2 
Me2NNMe2 
0.0070 ± 
0.0003 
0.05 ± 0.02 
0.03 ± 0.02 
(0.6)n.s. 
0.06 ± 0.02 
0.041 ± 
0.004 
(0.68)n.s. 
1.0 ± 0.9 
Dp44mT 
n.t. 0.06 ± 0.01 0.2 ± 0.1 
0.070 ± 
0.008 
n.t. 0.4 ± 0.5 
*** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, n.s. not significantly different, calculated by student´s T test with 
Welch´s correction 
Despite their similarities in IC50 values (except Me2NNMe2), the morphological evaluations of 
the treated cells revealed distinct differences between the tested derivatives (exemplary images 
taken after 48 h incubation time are shown in Figure 3A). In general, the tested substance panel 
could be divided into two categories based on the induction of characteristic morphologic 
phenotypes: 1) induction of massive cell flattening resulting in distinctly increased cell size and 
surface area (especially pronounced for Triapine, H2NNHMe, and MeHNNH2), in contrast to 2) 
mild cell flattening accompanied by appearance of vesicular blebbing in the cytosol (Figure 3B; 
especially pronounced for MeHNNMe2, Me2NNHMe, and the nanomolar cytotoxic 
Me2NNMe2). Based on already available data for the nanomolar derivative Dp44mT
27,13,34, this 
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could indicate a structure-dependently increasing impact of the compounds on lysosomal 
compartments.  
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Figure 3: A) Phase contrast images of SW480 cells treated with 2.5 µM of the indicated drugs 
for 48 h (200 x-magnification). B) Vacuoles in SW480 cells induced by 24 h treatment of 
Me2NNMe2 shown at 400 x-magnification. At early time points, vacuolization was 
predominantly perinuclear, but eventually the vacuoles fill the entire cytoplasmic space. Scale 
bar: 10 µm.  
 
Recently, Ishiguro et al. showed that Triapine differs from the terminally dimethylated nanomolar 
cytotoxic Dp44mT and P44mT (pyridine-2-carboxaldehyde 4,4-dimethyl-3-thiosemicarbazone) 
in its interaction with copper ions.25 Thus, we investigated the impact of pre-incubation with 
CuCl2 on the activity of our thiosemicarbazone panel (Figure 4). In agreement with the published 
data, CuCl2 (when given in excess or at least in a 1:1 ratio) had potent protective effects towards 
Triapine. In contrast, the nanomolar derivative Me2NNMe2 was highly synergistic with CuCl2 
(with combination indices (CI values) down to 0.02, Supporting Information Figure S1), which is 
in line with the data on the nanomolar Dp44mT (Figure S2) and P44mT.25 In addition, strong 
synergism with CuCl2 was also observed for MeHNNMe2, Me2NNH2, Me2NNHMe and at 
higher concentrations with H2NNMe2 and MeHNNHMe (the strongest effects were observed for 
MeHNNMe2 where CI values below 0.0001 were calculated, Figure S1). 2′,7′-
Dichlorofluorescein diacetate (DCF-DA) staining experiments suggested that this higher 
cytotoxic activity in the presence of CuCl2 is associated with induction of reactive oxygen species 
(ROS; Figure 5A). As higher drug concentrations of Me2NNHMe and Me2NNMe2 (5 µM drug 
with 10 µM CuCl2) decreased the DCF-DA signals to the level of untreated cells, tests for 
membrane integrity using the fluorescent dye propidium iodide (PI) were performed. These 
indicated that at the given conditions massive necrotic cell death (~80% of the cells were found 
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to be PI-positive) occurred (Figure 5B). Consequently, the lack of DCF-DA signal in these cells 
might be explained by enhanced membrane permeability (due to treatment-induced ROS) and 
consequently, reduced retention of DCF inside the cells. 
 
Figure 4: Impact of structural modifications of Triapine on the cytotoxicity in the presence of 
Cu(II) ions. Briefly, after 60 min pre-incubation with CuCl2 (10 and 30 µM), SW480 cells were 
treated for 72 h with the indicated concentrations of Triapine and its derivatives. Viability was 
determined using MTT assay. The values given are the mean ± the standard deviation of 
triplicates from one representative experiment out of three. 
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Figure 5: A) Intracellular ROS production in HL-60 cells after 30 min treatment of Triapine or 
its derivatives and prior 15 min incubation with CuCl2. As positive control, H2O2 was used. DCF-
DA fluorescence was measured using flow cytometry. B) Percentage of dead cells in conditions 
according to the DCF-DA assay. Cells were stained with Hoechst/PI and the percentage of PI-
positive cells was determined microscopically. 1:1 and 1:2 is the ligand to copper(II) ion ratio. 
The values given are the mean ± the standard deviation of three experiments. Significances were 
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established using one-way ANOVA with Bonferroni`s multiple comparison test (*** p ≤ 0.001; ** 
p≤ 0.01, * p≤ 0.05). 
Discussion and Conclusion 
Thiosemicarbazones are known for their promising biological activity, which resulted in their 
clinical development as anticancer drugs. The best investigated agents of this class of compounds 
are Triapine and Dp44mT7, 8,35 Noteworthy, Triapine has been tested in multiple clinical trials, 
showing promising activity in hematological diseases13, 14. However, there is so far no proof of 
anticancer activity of Triapine when given as mono-treatment against solid tumors36. The reasons 
for this are widely unexplored and make the development of novel thiosemicarbazone-based 
drugs interesting. Dp44mT has been well studied in multiple preclinical studies, indicating that 
this compound strongly differs from Triapine in several aspects. For example, Dp44mT was 
characterized by a distinctly higher (IC50 ~ nM) anticancer activity and a very high affinity for 
copper(II) ions26,13,27. Also some of the thiosemicarbazone derivatives developed from our group 
shared this shift of activity to the nM range23. Our data indicated that this pronounced anticancer 
activity is associated with terminal nitrogen dimethylation but only in the absence of any NH2 
functionality in the thiosemicarbazone backbone. Noteworthy, this increased activity was not 
accompanied by a similar increase in ribonucleotide reductase inhibition23.  
In the here presented study, the structure-activity relationship of Triapine derivatives was 
investigated in detail using the complete panel of stepwise methylated Triapine analogues. Our 
new panel was synthesized with the aim to allow detailed structure-activity/mode of action 
studies as well as development of novel derivatives to overcome Triapine resistance. Overall, 
several (rather unexpected) conclusions can be drawn from our results: 1) in contrast to the 
expected correlation of increased methylation of Triapine with changes in physico-chemical 
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properties, the Me2NNR2 series showed unexpected behavior in terms of lipophilicity and 
characteristics of the UV/vis spectra. Subsequent studies revealed that this is based on 
isomerization and stabilization of a different isomer in buffered aqueous solution. Therefore, 
simple prediction of physico-chemical properties does not seem to be possible for this class of 
compounds. 2) The shift of the cytotoxic activity to the nanomolar range was only observed for 
one derivative namely: Me2NNMe2. This means that already the presence of only one hydrogen 
atom either at the terminal nitrogen or at the aminopyridine nitrogen distinctly reduced the 
anticancer potential of the drug by ~100–1000-fold. This is in contrast to some reports on several 
Richardson-type dipyridyl complexes, which did not follow this structure activity relationship 
when tested on SK-N-MC neuroepithelioma cells22, 37. In detail, in this cell line several of 
Richardson’s complexes with terminal NHR-moiety (R = methyl, ethyl, phenyl or allyl) were of 
similar activity like the terminally dimethylated Dp44mT. However, a study of the same 
complexes in 28 different cell lines revealed an average IC50 value of 0.03±0.01 µM for 
Dp44mT, whereas the four thiosemicarbazones with terminal NHR had average IC50 values of 
0.20–1.70 µM21. Thus, these average cytotoxicity data followed the trend of our study with 
distinctly increased activity of compounds without any NH group. Noteworthy, these data also 
suggest that the activity enhancement by complete dimethylation is cell context-dependent, which 
is in agreement with our data revealing much stronger differences in case of A2780 compared to 
SW480 cells. 3) The impact of Triapine resistance on the activity of the novel derivatives was 
strongly associated with methylation of the pyridine and terminal NH2 group. SW480/Tria cells 
were cross-resistant or equally active to compounds with only mono-methylation of one or both 
NH2-groups (H2NNHMe, MeHNNH2 and MeHNNHMe). In contrast, all compounds with at 
least one NH2-dimethylation were not affected by the Triapine-resistance of SW480/tria. This 
clearly indicates that dimethylation of one of the two amino groups is a valuable tool to 
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efficiently overcome acquired Triapine resistance and suggests a different mode of action. 
Furthermore, it shows that the nanomolar activity is not mandatory for circumventing Triapine 
resistance. 4) Preliminary studies using ABCB1-overexpressing cells indicate that the impact of 
this efflux pump differs within the Triapine derivatives. Such, in agreement to our previous 
publication19, KBC-1 displayed a weak resistance to Triapine and closely related derivatives like 
H2NNHMe, MeHNNH2, MeHNNHMe. In contrast, drug resistance was reduced (not 
significant) by terminal dimethylation. Dimethylation at the pyridine NH2 in case of Me2NNH2 
and Me2NNHMe induced significant collateral sensitivity of KBC-1 cells. The nanomolar 
Me2NNMe2 showed no significant differences between KB-3-1 and KBC-1. This is in contrast to 
data on Dp44mT, where induction of collateral sensitivity was recently published in KBV-1 
cells34, 35 and might indicate some differences between Dp44mT and our nanomolar compound. 
5) The observed hyper-activity on Triapine-resistant cancer cells positively correlated with the 
appearance of vesicular blebbing. This is a first hint on the molecular differences between 
classical thiosemicarbazone like Triapine and novel derivatives especially those with three and 
four methyl groups (MeHNNMe2, Me2NNHMe as well as the nanomolar Me2NNMe2) which are 
able to circumvent Triapine resistance. 6) Also with respect to the interaction with copper(II) 
ions, distinct differences were observed in our study. Thus, compounds which are inefficient 
against SW480/Tria cells, also showed reduced cytotoxicity in the presence of copper(II) ions. In 
contrast, hyperactive compounds (again especially MeHNNMe2, Me2NNHMe, and the 
nanomolar Me2NNMe2) were highly synergistic with copper(II) treatment accompanied by 
induction of ROS and massive necrotic cell death. In general, ROS production by Me2NNMe2 is 
not surprising, as it is in good agreement with data on Dp44mT, reporting copper-dependent ROS 
production by this thiosemicarbazone with nanomolar cytotoxicity25, 27. However, our data 
indicate that the increased cytotoxicity in the presence of copper(II) ions is not the (only) reason 
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for the nanomolar activity of some thiosemicarbazones, as also MeHNNMe2 and Me2NNHMe 
with a low micromolar cytotoxicity show this synergistic effect. Noteworthy, the reasons 
underlying this very specific interaction with copper ions are still not fully understood. Ishiguro 
et al., for example, suggested that copper(II) complexes of Triapine and, in general, 
thiosemicarbazones without terminal dimethylation are able to get desulfurized in aqueous basic 
media with formation of insoluble CuS25. However, as already indicated by Ishiguro et al., our 
previous solution equilibrium studies on Triapine and several related derivatives, did not show 
any indications for such an irreversible process. In contrast, Lovejoy et al. suggested that due to 
its “polyprotic nature”, Dp44mT is specifically trapped in the acidic lysosomes after protonation 
of the first pyridyl moiety and subsequent copper binding by the second resulting in formation of 
a positively charged copper complex27. Noteworthy, despite several similarities to Dp44mT, all 
our derivatives contain only one pyridyl group. Consequently, the mechanisms suggested for 
cytotoxic activity of Dp44mT cannot explain the differences observed with regard to the 
interaction with copper in our study. Solution equilibrium studies showed that terminal 
dimethylation of thiosemicarbazones significantly increased the copper(II) binding abilities 
compared to derivatives with a terminal NH2 moiety
38. However, already the stability of the 
copper(II) complex in case of Triapine is outstandingly high with >99% [CuL]+ at 1 M at pH 
7.4. Thus, also the stability does not seem to be the crucial parameter and probably other factors 
like the thermodynamics and kinetics of the reduction process in the cellular environment are 
important. These studies are currently in progress in our group. Nevertheless, the rapid necrotic 
cell death observed with some derivatives in the presence of copper should be also considered 
carefully with respect to a possible application in vivo. Especially as it is well known that 
induction of necrosis can result in inflammatory reactions of the body39. Moreover, it has to be 
considered that various cancer types are frequently associated high serum copper levels40, 41 
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Consequently, treatment of such patients with copper-synergizing thiosemicarbazones might be 
associated with increased occurrence of adverse effects due to ROS production. 
Summarizing, we systematically synthesized a panel of N-methylated Triapine derivatives and 
investigated their biological modes of action. Our data gave new insights into the coherences 
between methylation, cross-resistance to Triapine, nanomolar cytotoxicity and synergism with 
copper(II) ions. The data, on the one hand, reveal that step-wise methylation of Triapine results in 
a change of the mode of action, which might be associated with the interaction of the intracellular 
copper balance. However, on the other hand, these effects do not seem to be responsible for the 
increased cytotoxic activity of some derivatives into the nanomolar range. 
 
Experimental Section 
tert-Butyl-(2-bromopyridin-3-yl)carbamate (1), tert-butyl (2-formylpyridin-3-yl)carbamate (2), 
Triapine and H2NNMe2 were synthesized as previously reported
23. All other solvents and 
chemicals were purchased from commercial suppliers und used without further purification. 
Elemental analyses were performed by the Microanalytical Laboratory of the University of 
Vienna and are within 0.4%, confirming >95% purity. All chromatographic separations were 
performed on silica gel. UV/vis spectra were recorded on an Agilent 8453 spectrophotometer 
from 200 to 1000 nm in PBS buffer pH 7.4 (<0.5% DMSO). ESI-MS spectrometry was carried 
out with a Bruker Esquire3000 ion trap spectrometer (Bruker Daltonics, Bremen, Germany). 
Expected and experimental isotope distributions were compared. 1H and 13C one- and two-
dimensional NMR spectra were recorded in DMSO-d6, with a Bruker Avance III 500 MHz FT-
NMR spectrometer at 500.10 (1H) and 125.75 (13C) MHz at 298 K. The residual 1H and 13C 
present in DMSO-d6 were used as internal references. Abbreviations for NMR data: py = 
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pyridine, Cq, py = quaternary carbon of pyridine. The fast relaxation of the HCl salts MeHNNH2 
and MeHNNHMe prevented the exact assignment of all protons and the detection of all carbon 
signals. Fluorescence measurements were performed on a Horiba FluoroMax®-4 
spectrofluorometer and processed using the FluorEssence v3.5 software package. All tested 
solutions had a concentration of 1×10−5 M. Scans were run at room temperature in 1% 
DMSO/PBS pH 7.4 with excitation and emission slit widths of 4 nm. 
 
Synthesis 
3-aminopyridine-2-carbaldehyde N-methylthiosemicarbazone (H2NNHMe). tert-Butyl (2-
formylpyridin-3-yl)carbamate (2) (147 mg, 0.66 mmol) was dissolved in EtOH (3 mL)/H2O (1 
mL) and 4-methylthiosemicarbazide (70 mg, 0.59 mmol) as well as conc. HCl (0.3 mL) were 
added. The reaction mixture was refluxed for 3 h and cooled to RT. The precipitate was filtered, 
washed with EtOH and dried in vacuo. H2NNHMe∙HCl was dissolved in water at 70 °C and 10% 
aq. NaHCO3 (0.8 mL) was added. After 1 h the precipitate was filtered off, washed with cold 
EtOH and Et2O and dried in vacuo. Yield: 110 mg (89%). Anal. Calcd. for C8H11N5S (Mr 209.27 
g/mol): C, 45.91; H, 5.30; N, 33.47; S, 15.32. Found: C, 45.57; H, 5.47; N, 33.27; S, 15.12. 
UV/vis (PBS), λmax, nm (ɛ, M
−1 cm−1): 259 (17800), 284 (17470), 359 (23750). ESI-MS in 
MeOH (negative): m/z 210 [M+H]+. 1H NMR (DMSO-d6): δ 11.35 (s, 1H, N-NH), 8.35–8.29 (m, 
2H, HC=N and NHCH3), 7.84 (dd, 
3J = 4 Hz, 4J = 1 Hz, 1H, Hpy), 7.16 (dd, 
3J = 8 Hz, 4J = 1 Hz, 
1H, Hpy), 7.08 (dd, 
3J = 8 Hz, 3J = 4 Hz, 1H, Hpy), 6.46 (s, 2H, NH2), 3.03 (d, 
3J = 4 Hz, 3H, 
NHCH3) ppm. 
13C NMR (DMSO-d6): δ = 177.6 (C=S), 149.3 (C=N), 144.3 (Cq, py), 137.7 (Cpy), 
133.5 (Cq, py), 124.8 (Cpy), 122.7 (Cpy), 31.7 (CH3) ppm. 
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tert-Butyl (2-bromopyridin-3-yl)(methyl)carbamate (3). tert-Butyl-(2-bromopyridin-3-
yl)carbamate (1) (1.0 g; 3.66 mmol) was dissolved in dry DMF (20 mL) at 0 °C and 60% NaH in 
mineral oil (183 mg, 4.58 mmol) was slowly added. The solution was stirred for 20 min and MeI 
(0.26 mL, 4.18 mmol) was added drop-wise. After 30 min at 0 °C the solution was additionally 
stirred for 1 h at RT. The reaction was quenched with water (20 mL) and the solvents were 
evaporated under reduced pressure. The residue was dissolved in water and extracted with Et2O. 
The organic layers were washed with H2O, 0.1 M HCl, sat. NaHCO3 solution and brine, dried 
over Na2SO4, evaporated under reduced pressure and dried in vacuo. n-Hexane was added to 
precipitate the product. The product was used without further purification. Yield: 0.84 g (85%). 
1H NMR (DMSO-d6): δ 8.37–8.30 (m, 1H, Hpy), 7.90 (dd, 
3J = 8 Hz, 4J = 2 Hz, 1H, Hpy), 7.51 
(dd, 3J = 5 Hz, 3J = 8 Hz, 1H, Hpy), 3.11 and 3.08 (s, 3H, NCH3), 1.48 and 1.30 (s, 9H, (CH3)3) 
ppm. 
 
tert-Butyl (2-formylpyridin-3-yl)(methyl)carbamate (4). Compound 3 (1.0 g; 3.48 mmol) was 
dissolved in dry THF (15 mL) at −78 °C and n-BuLi (2.6 mL, 4.18 mmol) was slowly added. 
After 1 h, DMF (0.31 mL, 4.18 mmol) was added and the reaction mixture was allowed to slowly 
warm up to RT. Subsequently, after addition of 1.5 M HCl (1.5 mL) the pH was adjusted to about 
7 with Na2CO3. The solution was extracted with EtOAc (3x), H2O (2x) and brine (1x), dried over 
Na2SO4, evaporated under reduced pressure and dried in vacuo. Yield: 0.69 g (82%). 
1H NMR 
(DMSO-d6): δ 10.01 (br. s, 1H, CHO), 8.70 (dd, 
3J = 5 Hz, 
4J = 1 Hz, 1H, Hpy), 7.94 (dd, 
3J = 8 
Hz,  4J = 1 Hz, 1H, Hpy), 7.73 (dd, 
3J = 8 Hz, 3J = 5 Hz, 1H, Hpy), 3.15 (br. s, 3H, NCH3), 1.46 
and 1.23 (s, 9H, (CH3)3) ppm. 
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3-(methylamino)pyridine-2-carbaldehyde thiosemicarbazone hydrochlorid (MeHNNH2). 
The synthesis of MeHNNH2 was already reported in literature, but using a different synthetic 
strategy42.  Compound 4 (100 mg, 0.42 mmol) was dissolved in EtOH (3.5 mL)/H2O (0.65 mL) 
and thiosemicarbazide (42.4 mg, 0.47 mmol) as well as conc. HCl (176 µL) were added. The red 
solution was refluxed for 4 h and cooled to RT. The orange precipitate was isolated by filtration, 
washed with cold EtOH and dried in vacuo. Yield: 81 mg (78%). Anal. Calcd. for C8H11N5S∙HCl 
(Mr = 245.73 g/mol): C, 39.10; H, 4.92; N, 28.50. Found: C, 39.10; H, 5.00; N, 28.23. ESI-MS in 
MeOH (negative): m/z 208 [M−HCl−H]−. UV/vis (PBS), λmax, nm (ɛ, M
−1 cm−1): 263 (10690), 
291 (11620), 383 (11370). 1H NMR (DMSO-d6): δ 11.84 (s, 1H, NH), 8.51 (s, 1H), 8.41 (s, 2H), 
8.02 (d, 3J = 8 Hz, 1H), 7.58 (br. s, 2H), 7.27 (v. br. s, 1H), 2.94 (s, 3H, NCH3) ppm. 
13C NMR 
(DMSO-d6): δ = 178.6 (C=S), 145.8 (Cq, py), 129.0 (Cq,py), 126.7 (Cpy), 124.5 (Cpy), 30.3 
(NHCH3) ppm (due to the fast relaxation of the HCl salt not all of the 
13C signals could be 
observed).  
 
3-(methylamino)pyridine-2-carbaldehyde N-methylthiosemicarbazone hydrochlorid 
(MeHNNHMe). Compound 4 (98.7 mg, 0.418 mmol) was dissolved in EtOH (1.15 mL)/H2O 
(0.55 mL) and 4-methylthiosemicarbazide (34.8 mg, 0.46 mmol) as well as conc. HCl (0.15 mL) 
were added. The solution was refluxed for 3 h and cooled to RT. The orange precipitate was 
separated by filtration, washed with cold EtOH and dried in vacuo. Yield: 87 mg (80%). Anal. 
Calcd. for C9H13N5S∙HCl (Mr = 223.30 g/mol): C, 41.61; H, 5.43; N, 26.96. Found: C, 41.59; H, 
5.43; N, 26.89. ESI-MS in MeOH (negative): m/z 222 [M−HCl−H]−. UV/vis (PBS), λmax, nm (ɛ, 
M−1 cm−1): 267 (15323), 286 (15334), 383 (14583). 1H NMR (DMSO-d6): δ 12.01 (s, 1H, N-
NH), 9.01 (s, 1H, NH), 8.38 (s, 1H, HC=N), 8.03 (dd, 3J = 5 Hz, 4J = 2 Hz, 1H, Hpy), 7.66 − 7.57 
(m, 2H, Hpy), 7.39 (v. br. s., 1H, NH), 3.06 (d, 3H, 
3J = 5 Hz, S=CNHCH3), 2.95 (s, 3H, 
31 
 
CqpyNHCH3) ppm. 
13C NMR (DMSO-d6): δ = 178.3 (C=S), 145.7 (Cq, py), 129.4 (Cpy), 126.5 
(Cpy), 122.9 (Cq, py), 31.6 (S=CNHCH3), 30.3 (CpyNHCH3) ppm (due to the fast relaxation of the 
HCl salt not all of the 13C signals could be observed). 
 
3-(methylamino)pyridine-2-carbaldehyde N,N-dimethylthiosemicarbazone hydrochlorid 
(MeHNNMe2). Compound 4 (100 mg, 0.42 mmol) was dissolved in EtOH (1.15 mL)/H2O (0.55 
mL) and 4,4-dimethyl-3-thiosemicarbazide (50 mg, 0.42 mmol) as well as conc. HCl (133 µL) 
were added. The solution was refluxed for 4 h and stored at 4 °C overnight. The brown 
precipitate was separated by filtration, washed with cold isopropanol and dried in vacuo. Yield: 
62 mg (54%). Anal. Calcd. for C10H15N5S·HCl (Mr = 273.73 g/mol): C, 43.87; H, 5.89; N, 25.58; 
S, 11.71. Found: C, 43.85; H, 5.92; N, 25.36; S, 11.75. ESI-MS in MeOH (negative): m/z 236 
[M−HCl−H]−. UV/vis (PBS), λmax, nm (ɛ, M
−1 cm−1): 264 (22980), 288 (13530), 384 (14860). 1H 
NMR (DMSO-d6): δ 12.15 (s, 1H, N-NH), 9.55 (br. s, 1H, NHCH3), 8.96 (s, 1H, HC=N),  8.02 
(dd, 3J = 4 Hz, 4J = 2 Hz, 1H, Hpy), 7.73 − 7.65 (m, 2H, Hpy), 3.37 (s, 6H, N(CH3)2), 3.04 (s, 3H, 
NHCH3) ppm. 
13C NMR (DMSO-d6): δ = 180.2 (C=S), 145.3 (Cq, py), 138.8 (C=N), 128.5 (Cq, py), 
128.2 (Cpy), 126.0 (Cpy), 124.2 (Cpy), 41.7 (N(CH3)2), 30.3 (NCH3) ppm. 
 
2-bromo-N,N-dimethylpyridin-3-amine (5). 3-Amino-2-bromopyridine (1.5 g, 8.67 mmol) was 
dissolved in dry DMF (30 mL) at 0°C and 60% NaH (956 mg, 23.9 mmol) was slowly added. 
The solution was stirred for 20 min and MeI (1.24 mL, 19.94 mmol) was added drop-wise. After 
30 min at 0 °C and 1 h at RT the reaction was quenched with water (3 mL). The solvents were 
evaporated under reduced pressure, the residue dissolved in water and extracted with Et2O. The 
organic layer was washed with H2O, 0.1 M HCl, sat. NaHCO3 solution and brine, dried over 
Na2SO4, evaporated under reduced pressure and dried in vacuo. The mineral oil was removed by 
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column chromatography (pure n-hexane and subsequently pure ethyl acetate to elute the product). 
Yield: 1.24 g (71%). 1H NMR (DMSO-d6): δ 8.01 (dd, 
3J = 5 Hz, 4J = 2 Hz, 1H, Hpy), 7.56 (dd, 
3J 
= 8 Hz, 4J = 2 Hz, 1H, Hpy), 7.38 (dd, 
3J = 8 Hz, 
3J = 5 Hz,
 1H, Hpy), 2.76 (s, 6H, NCH3) ppm. 
 
3-(dimethylamino)picolinaldehyde (6). Compound 5 (600 mg; 2.98 mmol) was dissolved in dry 
THF (12 mL), cooled to −78°C and n-BuLi (3.8 mL, 5.96 mmol) was slowly added. After 1 h 
DMF (0.3 mL, 3.87 mmol) was added and the reaction mixture was allowed to slowly warm up 
to RT. Subsequently, 1 M HCl (2 mL) was added and the pH adjusted to about 7 with Na2CO3. 
The product was extracted with EtOAc (3x) and washed with H2O (2x) and brine (1x), dried over 
Na2SO4, evaporated under reduced pressure and dried in vacuo. Purification was performed via 
column chromatography (EtOAc:hexane, 6:1) Yield: 0.24 g (54%). 1H NMR (DMSO-d6): δ 9.93 
(d, J = 1 Hz, 1H, CHO), 8.20 (dd, 3J  = 4 Hz, 
4J = 1 Hz, 1H, Hpy), 7.53 − 7.50 (m, 1H, Hpy), 7.46 
(dd, 3J = 9 Hz, 3J = 4 Hz, 1H, Hpy), 2.91 (s, 6H, NCH3) ppm. 
 
3-(dimethylamino)pyridine-2-carbaldehyde thiosemicarbazone (Me2NNH2). Compound 6 
(150 mg, 1.00 mmol) was dissolved in EtOH (2 mL)/H2O (1 mL) and thiosemicarbazide (91 mg, 
1.00 mmol) was added. The reaction mixture was refluxed for 3 h, cooled to RT and the solvent 
was removed under reduced pressure. Purification was performed via column chromatography. 
Pure ACN was used until the first impurity had been eluted and afterwards ACN:MeOH (9:1). 
Yield: 94 mg (42%). Anal. Calcd. for C9H13N5S (Mr = 223.30 g/mol): C, 48.41; H, 5.87; N, 
31.36; S, 14.36. Found: C, 48.32; H, 5.89; N, 31.16; S, 14.25. ESI-MS in MeOH (positive): m/z 
246 [M+Na]+. UV/vis (PBS), λmax, nm (ɛ, M
−1 cm−1): 292 (14190), 348 (9530). 1H NMR 
(DMSO-d6): E isomer δ 11.59 (s, 1H, NH), 8.41 (s, 1H, HC=N), 8.26 (s, 1H, NH2),  8.23 (dd, 
3J 
= 5 Hz, 4J = 1 Hz, 1H, Hpy), 7.52 (dd, 
3J = 8 Hz, 4J = 1 Hz, 1H, Hpy), 7.50 (s, 1H, NH2), 7.33 (dd, 
33 
 
3J = 8 Hz, 3J = 5 Hz, 1H, Hpy), 2.74 (s, 6H, N(CH3)2). 
13C NMR (DMSO-d6): E isomer δ = 178.8 
(C=S), 149.9 (Cq, py), 144.4 (Cq, py), 142.8 (Cpy), 141.9 (C=N), 126.3 (Cpy), 124.8 (Cpy), 44.7 
(N(CH3)2) ppm.  
Synthesis of the pure Z isomer: 20 mg of the pure E isomer were dissolved in 20 mL acetonitrile 
and stirred at 37°C for 24 h. After removal of the solvent, pure Z isomer was isolated after 
column chromatography with 100% acetonitrile as eluent.  
1H NMR (DMSO-d6): Z isomer δ 13.92 (s, 1H, NH), 8.53 (s, 1H, NH2),  8.35 (dd, 
3J = 5 Hz, 4J = 
1 Hz, 1H, Hpy), 8.18 (s, 1H, NH2), 7.71 (dd, 
3J = 8 Hz, 4J = 1 Hz, 1H, Hpy), 7.49 (s, 1H, HC=N), 
7.47 (dd, 3J = 8 Hz, 3J = 5 Hz, 1H, Hpy), 2.82 (s, 6H, N(CH3)2) ppm. 
13C NMR (DMSO-d6): Z 
isomer δ = 179.3 (C=S), 150.4 (Cq, py), 144.2 (Cq, py), 141.4 (Cpy), 131.2 (C=N), 128.0 (Cpy), 125.6 
(Cpy), 45.0 (N(CH3)2) ppm. 
 
3-(dimethylamino)pyridine-2-carbaldehyde N-methylthiosemicarbazone (Me2NNHMe). 
Compound 6 (70 mg, 0.47 mmol) was dissolved in EtOH (2 mL) and 4-methylthiosemicarbazide 
(49.5 mg, 0.47 mmol) was added. The solution was stirred for 1 h at RT and 4 h at 50°C. 
Subsequently, the solvent was evaporated under reduced pressure. Purification was performed via 
column chromatography using ACN/CHCl3 (10:1) and ACN/MeOH (95:5) for final elution of the 
product. Yield: 93 mg (83%). Anal. Calcd. for C10H15N5S (Mr 237.32 g/mol): C, 50.61; H, 6.37; 
N, 29.51; S, 13.51. Found: C, 50.57; H, 6.39; N, 29.23; S, 13.51. ESI-MS in MeOH (negative): 
m/z 236 [M−H]−. UV/vis (PBS), λmax, nm (ɛ, M
−1 cm−1): 290 (26410), 348 (19380). 1H NMR 
(DMSO-d6): E isomer δ 11.60 (s, 1H, N-NH), 8.42 (s, 1H, HC=N), 8.25 (dd, 
3J = 4 Hz, 4J = 1 Hz, 
1H, Hpy), 8.20 – 8.16 (m, 1H, NHCH3), 7.52 (dd, 
3J = 8 Hz, 4J = 1 Hz, 1H, Hpy), 7.33 (dd, 
3J = 8 
Hz, 3J = 4 Hz, 1H, Hpy), 3.04 (d, 
3J = 5 Hz, 3H, NHCH3), 2.74 (s, 6H, N(CH3)2). 
13C NMR 
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(DMSO-d6): E isomer δ = 178.5 (C=S), 150.0 (Cq, py), 144.8 (Cq. py), 142.9 (Cpy), 141.1 (C=N), 
126.2 (Cpy), 124.7 (Cpy), 44.8 (N(CH3)2), 31.4 (CH3) ppm.  
Synthesis of the Z isomer: 20 mg of the pure E isomer were dissolved in 8 mL acetonitrile and 
stirred at 37°C for 24 h. After removal of the solvent, pure Z isomer was isolated after column 
chromatography using 100% acetonitrile and for final elution acetonitrile/MeOH (95:5). 1H NMR 
(DMSO-d6): Z isomer δ 13.97 (s, 1H, N-NH), 8.86 (m, 1H, NHCH3), 8.34 (dd, 
3J = 5 Hz, 4J = 1 
Hz, 1H, Hpy), 7.71 (dd, 
3J = 4 Hz, 4J = 1 Hz, 1H, Hpy), 7.47 (s, 1H, HC=N), 7.46 (dd, 
3J = 8 Hz, 4J 
= 5 Hz, 1H, Hpy), 3.02 (d, 
3J = 5 Hz, 3H, NHCH3), 2.81 (s, 6H, N(CH3)2) ppm. 
13C NMR 
(DMSO-d6): Z isomer δ = 178.7 (C=S), 150.3 (Cq, py), 144.3 (Cq. py), 141.3 (Cpy), 130.8 (C=N), 
127.8 (Cpy), 125.5 (Cpy), 45.0 (N(CH3)2), 31.5 (CH3) ppm. 
 
3-(dimethylamino)pyridine-2-carbaldehyde N,N-dimethylthiosemicarbazone (Me2NNMe2). 
Compound 6 (107 mg, 0.71 mmol) was dissolved in EtOH (3 mL) and 4,4-dimethyl-3-
thiosemicarbazide (85 mg, 0.71 mmol) was added. The solution was stirred at RT for 1 h, at 50°C 
for 4 h and subsequently the solvent was evaporated under reduced pressure. Purification was 
performed via column chromatography using EtOAc/Hexane (9:1) an d EtOAc/MeOH (95:5) for 
final elution of the product. Finally, the product was stirred in diethylether (2 mL) at 35°C for 3 
h, the solid was filtered off and dried in vacuo. Yield: 60 mg (34%). Anal. Calcd. for C11H17N5S 
(Mr 251.35 g/mol): C, 52.56; H, 6.82; N, 27.86; S, 12.76. Found: C, 50.58; H, 6.77; N, 27.68; S, 
12.54. ESI-MS in MeOH (positive): m/z 252 [M+H]+. UV/vis (PBS), λmax, nm (ɛ, M
−1 cm−1): 280 
(19380), 352 (11750). 1H NMR (DMSO-d6): E isomer: 11.05 (s, 1H, NH), 8.49 (s, 1H, HC=N), 
8.25 – 8.22 (m, 1H, Hpy), 7.51 (dd, 
3J = 8 Hz, 4J = 1 Hz, 1H, Hpy), 7.30 (dd, 
3J = 8 Hz, 3J = 4 Hz, 
1H, Hpy), 3.31 (s, 6H, S=CN(CH3)2), 2.75 (s, 6H, CpyN(CH3)2). Z isomer δ 15.23 (s, 1H, NH), 
8.35 (dd, 3J = 5 Hz, 4J = 1 Hz, 1H, Hpy), 7.72 (dd, 
3J = 8 Hz, 4J = 1 Hz, 1H, Hpy), 7.71 (s, 1H, 
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HC=N), 7.46 (dd, 3J = 8 Hz, 3J = 5 Hz, 1H, Hpy), 3.36 (s, 6H, S=CN(CH3)2), 2.83 (s, 6H, 
CpyN(CH3)2) ppm. 
13C NMR (DMSO-d6): E isomer: δ 181.2 (C=S), 149.5 (Cq, py), 145.2 (Cq, py), 
143.0 (Cpy), 142.8 (C=N), 126.2 (Cpy), 124.4 (Cpy), 44.8 (CpyN(CH3)2), 42.7 (S=CN(CH3)2). Z 
isomer δ 180.6 (C=S), 149.9 (Cq, py), 144.3 (Cq, py), 140.1 (Cpy), 133.6 (C=N), 127.9 (Cpy), 125.2 
(Cpy), 45.0 (CpyN(CH3)2), 41.3 (S=CN(CH3)2) ppm. 
 
Crystallographic Structure Determination. X-ray diffraction measurements were performed on 
a Bruker D8 VENTURE system equipped with a multilayer monochromator and a Mo K/a 
INCOATEC microfocus sealed tube (λ = 0.71073 Å). A single crystal of approximate 
dimensions 0.30 mm x 0.20 mm x 0.10 mm, was coated with Paratone-N oil, mounted at room 
temperature on a Hampton Research 0.3-0.4 mm CryoLoop and cooled to 100 K under a stream 
of N2 maintained by a KRYOFLEXI low-temperature apparatus. The crystal was positioned at 35 
mm from the detector and 775 frames were collected, each for 10 s over 1° scan width. The data 
were processed using SAINT software43. The structures were solved by direct methods and 
refined by full-matrix least-squares techniques. Data were corrected for absorption effects using 
the multi-scan method (SADABS44). Non-hydrogen atoms were refined with anisotropic 
displacement parameters. Hydrogen atoms were placed at calculated positions and refined as 
riding atoms in the subsequent least squares model refinements. The isotropic thermal parameters 
were estimated to be 1.2 respectively 1.5 times the values of the equivalent isotropic thermal 
parameters of the atoms to which hydrogens were bound. The following computer programs were 
used: structure solution SHELXS-9745; refinement SHELXL-Version 2013/345, OLEX246; 
molecular diagrams ORTEP47; Processor: Intel Xeon CPU E3-1270 V2 @ 3.50GHz; scattering 
factors48.  
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Crystal data for Me2NNH2: C9H13N5S, Mr = 223.30, monoclinic, P21/c, a [Å] = 11.8688(4), 
b [Å]= 7.6283(3), c [Å] = 13.1597(5), β = 115.668(2), V = 1073.89(7) Å3, Z = 4, 
ρcalcd = 1.381 g/cm
3, μ = 0.276 mm-1, λ(Mo-Kα) = 0.71073 Å, T = 100 K, 2ϴmax = 60.27°, 17994 
reflections measured, 3162 unique (Rint = 0.0413), R1 = 0.0354, wR2 = 0.0931, GOF = 1.046. 
Crystallographic data have been deposited at the Cambridge Crystallographic Data Center with 
number CCDC1449031.    
Interconversion studies of the isomers by HPLC-MS. Sample preparation: DMSO stock 
solutions of the compounds were diluted with PBS (pH 7.4) to a final concentration of 50 µM 
(1% DMSO), followed by immediate LC-MS measurements. LC-MS system: The 
chromatographic separation was performed with an Atlantis T3 C18 reversed-phase column (150 
mm×2.1 mm, 3 μm particle size) from Waters (Milford, USA). As a mobile phase a gradient 
prepared from water containing 1 % (v/v) acetonitrile and 0.1 % (v/v) formic acid (eluent A) and 
acetonitrile containing 1 % (v/v) water and 0.1 % (v/v) formic acid (eluent B) was used. The 
mobile phase was kept constant at 10 % B for 1 min. Then, B was increased to 50 % within 5 min 
and kept for 2 min. Subsequently, B was increased to 90 % within 0.1 min and kept for 0.9 min to 
flush the column, followed by reconstitution of the starting conditions within 0.1 min and re-
equilibration with 10 % B for 8.9 min (total analysis time = 18 min). Due to the high affinity of 
thiosemicarbazones for metal ions even within a HPLC system, the measurements were carried 
out on an inert HPLC system (1260 Infinity Bio-inert Quaternary LC System, Agilent 
Technologies), controlled by an Agilent OpenLAB CDS ChemStation Edition Rev. C.01.06[61] 
software, coupled to an Amazon L electrospray ionization ion trap mass spectrometry system 
(Bruker Daltonics). The LC-MS runs were performed in positive ionization mode with the 
following optimized parameters: flow rate 0.2 mL/min, injection volume 5 μL, column 
temperature 25 °C and autosampler temperature 5 °C, drying gas 10 L/min (350 °C), nebulizer 
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pressure 35 psi and capillary voltage 4000 V. The HyStar 3.2 and Data Analysis 4.0 software 
package (Bruker Daltonics) were used for instrument control and data processing. 
Determination of the distribution coefficients (D7.4). D7.4 values of all compounds were 
determined by the traditional shake-flask method in n-octanol/buffered aqueous solution at pH 
7.4 at 25 ± 0.2 °C as described previously30. Two parallel experiments were performed for each 
sample. The compounds were dissolved at 30‒45 µM in the n-octanol pre-saturated aqueous 
solution of the buffer (10 mM HEPES) at constant ionic strength (0.10 M KCl). The aqueous 
solutions and n-octanol with 1:1 phase ratio were gently mixed with 360° vertical rotation for 3 h 
to avoid emulsion formation and the mixtures were centrifuged at 5000 rpm for 5 min by a 
temperature controlled centrifuge (Sanyo) at 25 °C. Estimated logP values of the neutral forms of 
the compounds were calculated using ChemDraw Ultra program (Version 10.0, 1986-2005 
Cambridge Soft.).    
Cell lines and culture conditions. The following human cancer cell lines were used in this 
study: the colon carcinoma-derived cell line SW480 and lung fibroblasts WI-38 (obtained from 
the American Tissue Culture Collection), the ovarian carcinoma-derived cell line A2780 
(obtained from Sigma-Aldrich), the acute promyelocytic leukemia-derived cell line HL-60 
(obtained from Dr. M. Center, Kansas State University), the cervix carcinoma-derived cell line 
KB-3-1 and the colchicine resistant subline KB-C-1 (obtained from Dr. D. W. Shen, Bethesda, 
Maryland). SW480 and WI-38 cells were grown in MEM with 10% FCS and A2780, KB-3-1, 
KB-C-1 and HL-60 cells were cultured in RPMI 1640 supplemented with 10% FCS. SW480/Tria 
cells were generated by continuous exposure of SW480 cells to increasing concentrations of 
Triapine (starting point 0.05 µM; end point 20 µM) over a period of one year19. Triapine was 
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administered to the cells once every other week at the day after passage, when cells had attached 
to the culture flasks.  
Synergism is expressed by the combination index (CI) according to Chou and Talalay49 using 
CalcuSyn software (Biosoft, Ferguson, MO, USA). CI < 0.9, CI = 0.9–1.2 or CI >1.2 represent 
synergism, additive effects and antagonism, respectively. 
Cytotoxicity tests in cancer cell lines. To determine cell viability, either 2 x 104 cells/mL of 
SW480, SW480/Tria, WI-38, KB-3-1 and KB-C-1 or 3 x 104 cells/mL of A2780 cells were plated 
on 96-well plates (100 µL/well) and allowed to recover for 24 h. Then, cells were exposed to the 
test drugs with the indicated concentrations for 72 h. In combination experiments the cells were 
pre-incubated for one hour with CuCl2 (10 or 30 µM). Anticancer activity was measured by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based vitality assay (EZ4U; 
Biomedica, Vienna, Austria) following the manufacturer’s recommendations. Cytotoxicity was 
calculated using the Graph Pad Prism software (using a point-to-point function) and was 
expressed as IC50 values calculated from full dose–response curves (drug concentrations inducing 
a 50% reduction of cell number in comparison to untreated control cells cultured in parallel).  
Microscopy. Phase contrast images (Figure 3A) were taken at a 200 x-magnification at the Nikon 
eclipse Ti-e fluorescence microscope after incubation with Triapine and its derivatives (2.5 µM) 
for 48 h. The magnified cells (Figure 3B) were photographed after 24 h of treatment at 400 x 
magnification at the Nikon eclipse Ti-e fluorescence microscope with a sCMOS pco.edge 
camera.  
Measurement of intracellular ROS. 2′,7′-Dichlorofluorescein diacetate (DCF-DA) was used to 
detect the production of ROS50. DCF-DA stock solutions (33.4 mM) in DMSO were stored at 
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−20 °C. HL-60 cells (5 × 105 cells per sample in 500 µL phenol-free Hanks balanced salt 
solution) were incubated with DCF-DA for 30 min. Subsequently, Triapine and its derivatives 
were added in the indicated concentrations for further 30 min. CuCl2 was added as indicated (1, 
2, 5 or 10 µM) to the samples 15 min prior to addition of the thiosemicarbazones. After 
incubation, the mean fluorescence intensity was measured by flow cytometry using a 
FACSCalibur instrument (Becton Dickinson, Palo Alto, CA, USA). A concentration of 200 μM 
H2O2 was used as the control.  
Hoechst 33258/PI - staining. A staining of Hoechst 33258 combined with propidium iodide (PI) 
was used to measure the percentage of dead cells. Therefore, HL-60 cells (5 × 105 cells per 
sample in 500 µL phenol-free Hanks balanced salt solution) were incubated with Hoechst/PI (1 
µg/mL / 2.5 µg/mL) for 30 min. Subsequently, Triapine and its derivatives were added in the 
indicated concentrations for further 30 min. CuCl2 was added as indicated (2, 5 or 10 µM) to the 
samples 15 min prior to addition of the thiosemicarbazones. Pictures were taken at 200 x-
magnification at the Nikon eclipse Ti-e fluorescence microscope and PI-positive cells were 
counted as percentage of Hoechst-positive cells. At least 300 cells were counted per sample. 
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